Schrodinger Inc. (SDGR) Social Stream
Featured Post From StockTwits About SDGR
$SDGR Selloff is unwarranted IMO. Good revenue growth from SW side of the business. Increased expenses are to drive further platform growth and to fund in-house clinical trials. Clinical stage biotech with upwards of 20% revenue growth w/ no approved drugs yet? Don't think you'll find that anywhere in biotech land. The deal w/ $NVDA is under appreciated as well. Very early innings of using this sort of simulation tool for chemistry/biochemistry. Quantum computing will unlock untold capability in chemical bond modeling. They are building the foundation for multi-decade growth. Many applications outside of bio that will unlock further growth for the SW business. Long, think we may see mid to low 50s but this is a buying opportunity.WatchingClosely, published August 12, 2021
What Else are SDGR Traders Talking About?
Other tickers frequently mentioned alongside SDGR is NVDA.